<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

qz
BioMarin is acquiring Alesta Therapeutics for $275 million to develop a first oral rare bone disease treatment

The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 50.45

Destination
Apple commits $500 million over several years to buy US-made rare earth magnets

Apple just announced a commitment of $500 million over several years to buy rare earth magnets from the US-based company MP Materials. These rare earth magnets are used in a number of products, includ [...]

Match Score: 46.30

Destination
The Shokz OpenFit 2 promises better sound and longer battery life

In 2023, Shokz strayed from its bone conduction roots with a pair of “air conduction” open-ear wireless earbuds. While the Shokz OpenFit delivered better audio than bone conduction models, that wa [...]

Match Score: 44.31

thenextweb
Cambridge biotech STORM Therapeutics raises $56M

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by e [...]

Match Score: 41.15

the-decoder
NYU professor fights AI cheating with AI-powered oral exams that cost 42 cents per student

An NYU professor ran oral exams using a voice AI agent. The experiment cost $15 for 36 students and revealed not just gaps in student knowledge, but weaknesses in his own teaching.<br /> The art [...]

Match Score: 40.78

Destination
Peter Thiel is utterly wrong about Alzheimer's

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal founder Peter Thiel. There's a reason it was published in the opinion sect [...]

Match Score: 39.78

Destination
Doctors successfully treated a baby with the first ever personalized gene-editing therapy

A team of doctors and scientists have successfully treated a rare genetic condition with the first-ever personalized gene-editing therapy. Results of the groundbreaking treatment have been published i [...]

Match Score: 39.28

thenextweb
UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease

The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseas [...]

Match Score: 37.96

Destination
The FDA clears the first blood test for diagnosing Alzheimer's disease

There's a new way to screen for early detection of Alzheimer's disease. On Friday, the Food and Drug Administration (FDA) cleared the first blood test for the disorder. Fujirebio Diagnostics [...]

Match Score: 35.92